DexCom's Stock Downgrade: Opportunity or Warning?
Update: 2025-09-08
Description
DexCom stock takes a hit after Oppenheimer downgrades it, citing competition concerns. Despite a recent positive outlook and new product buzz, the stock dipped 2% following the announcement. But it's not all bad news: DexCom is expanding access to its non-insulin diabetes products. Is this a buying opportunity or a sign of tougher times ahead for the medical device maker?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
